Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five YearsNefati Kıylıoğlu Adnan Menderes University Faculty of Medicine, Department of Neurology, Division of Clinical Neurophysiology, Aydın, Turkey
With the advent of new agents in the treatment of multiple sclerosis, new treatment modalities have emerged (escalation-induction therapy) and the increased efficacy of the drugs has led to increased drug-related risks. The risk/benefit balance has become more carefully assessed. The increased need for reliable markers to predict prognosis-disability has also led to an increase in research conducted in this area. In this short review, studies published between 2012-2017, especially those related to prognosis and disability, were compiled. Keywords: Multiple sclerosis, disability, prognosis, biomarker
Nefati Kıylıoğlu. Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years. Turk J Neurol. 2018; 24(3): 203-215
Corresponding Author: Nefati Kıylıoğlu, Türkiye |
|